Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC
riginally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin formulated with Sodium N-[8-(2-hydroxy benzoyl) amino] caprylate (SNAC).
Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19
Here are the potential human coronavirus vaccines/drugs pharmaceutical companies across the world are developing following the Wuhan coronavirus outbreak (COVID-19).
Janssen’s Stelara shows remission in Crohn’s disease patients
Interim results from the Phase IIIb STARDUST clinical trial have revealed that Janssen Pharmaceutical’s Stelara (ustekinumab) led to clinical remission in moderately to severely active Crohn's disease (CD) patients.
ImmunogenX starts enrolment in Phase IIb celiac disease study
Biotherapeutics company ImmunogenX has commenced patient enrolment in a Phase IIb clinical trial of Latiglutenase (IMGX003) for the treatment of celiac disease.
AbbVie reports positive data for Rinvoq in psoriatic arthritis
AbbVie has reported that the Phase III SELECT-PsA 1 study of Rinvoq (upadacitinib) has met its primary endpoint in adults with active psoriatic arthritis.
AstraZeneca studies Fasenra in three new trials for skin diseases
AstraZeneca has started three new clinical trials to evaluate monoclonal antibody Fasenra for the treatment of eosinophil-driven skin diseases.
Annexon launches Phase 1b study of ANX-005 in combination with IVIG in subjects with Guillain-Barré syndrome
Guillain-Barré syndrome is a rare autoimmune neurological disorder in which the immune system attacks the peripheral nervous system.
Blueprint’s Phase II avapritinib sparks concerns on risk-benefit profile
AdvSM is a rare condition indicated by the uncontrolled accumulation of neoplastic mast cells (MCs) in various organs.
Sanofi’s trial of sutimlimab meets primary and secondary endpoints
Sanofi has reported positive results from a pivotal Phase III trial of sutimlimab for the treatment of people with cold agglutinin disease (CAD), a serious, chronic, rare blood disorder.